View in EDS

An European Organisation for Research and Treatment of Cancer phase I study of lapatinib and docetaxel as neoadjuvant treatment for Human Epidermal Growth Factor Receptor 2 (HER2) positive locally-advanced/inflammatory or large operable breast cancer

Saved in:
Bibliographic Details
Title: An European Organisation for Research and Treatment of Cancer phase I study of lapatinib and docetaxel as neoadjuvant treatment for Human Epidermal Growth Factor Receptor 2 (HER2) positive locally-advanced/inflammatory or large operable breast cancer
Authors: Bonnefoi, H.1,2 Quincy@bergonie.org, Zaman, K.3, Debled, M.1, Fiche, M.3, Fournier, M.1, Nobahar, M.4, Pierga, J-Y5, Koch, K.M.6, Bartlett, J.7, Zimmer, A.8, Marreaud, S.8, Bogaerts, J.8, Cameron, D.7
Source: European Journal of Cancer. Jan2013, Vol. 49 Issue 2, p281-289. 9p.
Database: Academic Search Ultimate
Description
ISSN:09598049
DOI:10.1016/j.ejca.2012.08.006